The benefits and harms of deprescribing
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Deprescribing is the process of trial withdrawal of inappropriate medications. Currently, the strongest evidence for benefit of deprescribing is from cohort and observational studies of withdrawal of specific medication classes that have shown better patient outcomes, mainly through resolution of adverse drug reactions. Additional potential benefits of deprescribing include reduced financial costs and improved adherence with other medications. The harms of ceasing medication use include adverse drug withdrawal reactions, pharmacokinetic and pharmacodynamic changes and return of the medical condition. These can be minimised with proper planning (ie, tapering), monitoring after withdrawal, and reinitiation of the medication if the condition returns. More evidence is needed regarding negative, non-reversible effects of ceasing use of certain classes of medication, such as acetylcholinesterase inhibitors. Cessation of use has not been studied for many medication classes, and large-scale randomised controlled trials of systematic deprescribing are required before the true benefits and harms can be known.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Black, D. M., Schwartz, A. V., Ensrud, K. E., Cauley, J. A., Levis, S., Quandt, S. A., Satterfield, S., Wallace, R. B., Bauer, D. C., Palermo, L., et al. (2006) · JAMA · doi:10.1001/jama.296.24.2927 · Cited by 1,407
Ballard, C., Hanney, M. L., Theodoulou, M., Douglas, S., McShane, R., Kossakowski, K., Gill, R., Juszczak, E., Yu, L.-M., & Jacoby, R. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70295-3 · Cited by 567
Patient Barriers to and Enablers of Deprescribing: a Systematic Review
Reeve, E., To, J., Hendrix, I., Shakib, S., Roberts, M. S., & Wiese, M. D. (2013) · Drugs & Aging · doi:10.1007/s40266-013-0106-8 · Cited by 536
Self-citationDoody, R. S. (2001) · Archives of Neurology · doi:10.1001/archneur.58.3.427 · Cited by 362
Bain, K. T., Holmes, H. M., Beers, M. H., Maio, V., Handler, S. M., & Pauker, S. G. (2008) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2008.01916.x · Cited by 198
Kersten, H., Molden, E., Tolo, I. K., Skovlund, E., Engedal, K., & Wyller, T. B. (2013) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/gls176 · Cited by 131
Gurwitz, J. H., Field, T. S., Rochon, P., Judge, J., Harrold, L. R., Bell, C. M., Lee, M., White, K., LaPrino, J., Erramuspe‐Mainard, J., et al. (2008) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2008.02004.x · Cited by 106
Cited by
Reeve, E., Gnjidic, D., Long, J., & Hilmer, S. (2015) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12732 · Cited by 855
Self-citationAnderson, K., Stowasser, D., Freeman, C., & Scott, I. (2014) · BMJ Open · doi:10.1136/bmjopen-2014-006544 · Cited by 725
Reeve, E., Thompson, W., & Farrell, B. (2017) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2016.12.021 · Cited by 331
Self-citationAppropriate Polypharmacy and Medicine Safety: When Many is not Too Many
Cadogan, C. A., Ryan, C., & Hughes, C. M. (2016) · Drug Safety · doi:10.1007/s40264-015-0378-5 · Cited by 298
Reeve, E., Ong, M., Wu, A., Jansen, J., Petrovic, M., & Gnjidic, D. (2017) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-017-2257-8 · Cited by 192
Self-citation
Metadata
- Authors
- Reeve, E., Shakib, S., Hendrix, I., Roberts, M. S., & Wiese, M. D.
- Venue
- Medical Journal of Australia
- Publisher
- AMPCo
- Published
- 2014-10
- Volume
- 201
- Issue
- 7
- Pages
- 386-389
- ISSN
- 0025-729X (ISSN-L)
- 1326-5377
- OpenAlex
- W2007354199
- Cited by
- 113
- References
- 7
- FWCI
- 4.96
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The benefits and harms of deprescribing. https://app.cochat.ai/papers/10.5694/mja13.00200
- The paper
- Reeve, E., Shakib, S., Hendrix, I., Roberts, M. S., & Wiese, M. D. (2014). The benefits and harms of deprescribing. Medical Journal of Australia. https://doi.org/10.5694/mja13.00200
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.